Skip to main content
Dr Usman Javaid
Dr Usman Javaid
Gastroenterologist
Liver & Hepatology

Fatty Liver Disease (NAFLD / NASH) — treatment in Lahore

Also known as: NAFLD · MASLD · NASH · MASH · Hepatic Steatosis · Fatty Liver

Fatty liver disease — including non-alcoholic fatty liver disease (NAFLD) and its more advanced form non-alcoholic steatohepatitis (NASH) — is excessive fat accumulation in liver cells, often linked to obesity, diabetes, and metabolic syndrome.

Dr Usman Javaid
Medically reviewed
Dr Usman Javaid · MPH, FRSPH (UK)
Last reviewed
Evidence-based

Overview

Fatty liver often shows up incidentally on ultrasound. With targeted lifestyle change, metabolic care, and follow-up, many patients reverse it. For those with steatohepatitis, we stage and treat actively.

NAFLD affects 25–30% of adults globally and even higher percentages in South Asia
It is the most common cause of liver-enzyme elevation in Pakistan
It is the fastest-growing indication for liver transplant worldwide
A 7–10% weight loss reverses NAFLD in most patients

Signs & symptoms of Fatty Liver Disease (NAFLD / NASH)

If you recognize one or more of these, it may be worth a consultation:

  • Usually silent
  • Mild right-upper-abdominal fullness
  • Detected on routine ultrasound or LFTs
  • Often paired with diabetes or obesity

Causes & risk factors

Several factors can contribute to Fatty Liver Disease (NAFLD / NASH). Identifying yours guides the treatment plan.

  • Obesity and abdominal weight
  • Type 2 diabetes and insulin resistance
  • High triglycerides and low HDL
  • Sedentary lifestyle
  • Genetic susceptibility (PNPLA3, TM6SF2)
  • Certain medications (steroids, tamoxifen, amiodarone)

How Fatty Liver Disease (NAFLD / NASH) is diagnosed

We order tests selectively — only what changes the plan.

  • Liver function tests
  • Fasting glucose, HbA1c, lipids
  • Ultrasound, FibroScan
  • Hepatitis screening to exclude other causes

Treatment options

Treatment for Fatty Liver Disease (NAFLD / NASH) is personalized — the right plan depends on your symptoms, test results, and life situation.

  1. 1 Weight loss of 7–10% (the most effective single intervention)
  2. 2 GLP-1 receptor agonists (semaglutide, tirzepatide) in selected patients
  3. 3 Treatment of diabetes and dyslipidemia
  4. 4 Resmetirom (newly approved for NASH with significant fibrosis)
  5. 5 Vitamin E in selected non-diabetic NASH patients
  6. 6 FibroScan-based monitoring every 6–12 months
Prognosis & outlook

Simple fatty liver is largely reversible with sustained weight loss and metabolic optimization. Advanced fibrosis is less reversible but progression can usually be halted. Untreated NASH can progress to cirrhosis over 10–20 years.

Can Fatty Liver Disease (NAFLD / NASH) be prevented?

Simple, evidence-based steps that reduce your risk.

  • Maintain a healthy weight (BMI <23 for South Asians)
  • Mediterranean-style eating
  • 150 minutes of moderate activity weekly
  • Limit fructose and ultra-processed foods
  • Limit alcohol
  • Optimize diabetes and lipid control

When should you see a doctor about Fatty Liver Disease (NAFLD / NASH)?

Reach out without delay if you notice any of the following.

  • Fatty liver on routine ultrasound
  • Elevated liver enzymes (ALT, AST)
  • Diabetes plus liver enzyme elevation
  • BMI ≥30 (≥27 for South Asians) with metabolic syndrome
  • Family history of cirrhosis or HCC

Frequently asked questions about Fatty Liver Disease (NAFLD / NASH)

Is fatty liver dangerous? +

Most cases are mild and reversible, but a meaningful minority (~20%) progress to NASH with inflammation, and from there to fibrosis and cirrhosis over years. Identifying who is at risk — and intervening early — is the work of hepatology.

Can fatty liver be reversed? +

Yes — simple fatty liver (steatosis) is usually fully reversible with sustained 7–10% body-weight loss and metabolic optimization. NASH with fibrosis is harder to fully reverse but progression can be stopped.

Will GLP-1 drugs like Ozempic help fatty liver? +

Yes. GLP-1 receptor agonists (semaglutide) and dual agonists (tirzepatide) have shown measurable reduction in liver fat and improvement in NASH histology in clinical trials. They are increasingly used in metabolic fatty liver care.

Do I need a liver biopsy? +

Rarely. Non-invasive tests (FibroScan, MR elastography, FIB-4, NFS score) are highly accurate for staging fibrosis. Biopsy is reserved for diagnostic uncertainty or trial settings.

How often should I be monitored? +

For simple fatty liver: every 1–2 years. For NASH or any fibrosis: every 6–12 months. Once cirrhosis develops, every 6 months including liver cancer surveillance.

Dr Usman Javaid
Author & medical reviewer

Dr Usman Javaid

Gastroenterology & Medicine Diplomat · DIP (Gastro) UK · DIP (Hepatology) UK · DIP (Diabetes) UK · MCPS FM-TC · MPH · FRSPH (UK) · FRCP (Colombo) · Organ Transplant Advisor · CHPE (NUMS) · Preventive Medicine Specialist · Owner of Javaid Poly Clinic.

This page was medically reviewed by Dr Usman Javaid on . Content is updated when new evidence or guidelines emerge.

Medical disclaimer: This page is for educational purposes and does not replace medical consultation. If you have symptoms of Fatty Liver Disease (NAFLD / NASH) or any other condition, please book a consultation. In emergencies, call 1122 or visit your nearest emergency department.

A clear plan starts with a careful conversation.

If something feels off — pain, reflux, fatigue, jaundice, weight change — don't wait it out alone. Book a consultation and let's understand it together.

Call WhatsApp Book